337 related articles for article (PubMed ID: 15811373)
1. Atomic resolution structures of CTX-M beta-lactamases: extended spectrum activities from increased mobility and decreased stability.
Chen Y; Delmas J; Sirot J; Shoichet B; Bonnet R
J Mol Biol; 2005 Apr; 348(2):349-62. PubMed ID: 15811373
[TBL] [Abstract][Full Text] [Related]
2. Structure and dynamics of CTX-M enzymes reveal insights into substrate accommodation by extended-spectrum beta-lactamases.
Delmas J; Chen Y; Prati F; Robin F; Shoichet BK; Bonnet R
J Mol Biol; 2008 Jan; 375(1):192-201. PubMed ID: 17999931
[TBL] [Abstract][Full Text] [Related]
3. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.
Lewis JS; Herrera M; Wickes B; Patterson JE; Jorgensen JH
Antimicrob Agents Chemother; 2007 Nov; 51(11):4015-21. PubMed ID: 17724160
[TBL] [Abstract][Full Text] [Related]
4. Noncovalent interaction energies in covalent complexes: TEM-1 beta-lactamase and beta-lactams.
Wang X; Minasov G; Shoichet BK
Proteins; 2002 Apr; 47(1):86-96. PubMed ID: 11870868
[TBL] [Abstract][Full Text] [Related]
5. An engineered disulfide bond between residues 69 and 238 in extended-spectrum beta-lactamase Toho-1 reduces its activity toward third-generation cephalosporins.
Shimizu-Ibuka A; Matsuzawa H; Sakai H
Biochemistry; 2004 Dec; 43(50):15737-45. PubMed ID: 15595829
[TBL] [Abstract][Full Text] [Related]
6. The spread of CTX-M-type extended-spectrum beta-lactamases.
Rossolini GM; D'Andrea MM; Mugnaioli C
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():33-41. PubMed ID: 18154526
[TBL] [Abstract][Full Text] [Related]
7. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs.
Wang X; Minasov G; Shoichet BK
J Mol Biol; 2002 Jun; 320(1):85-95. PubMed ID: 12079336
[TBL] [Abstract][Full Text] [Related]
8. A novel extended-spectrum beta-lactamase CTX-M-23 with a P167T substitution in the active-site omega loop associated with ceftazidime resistance.
Stürenburg E; Kühn A; Mack D; Laufs R
J Antimicrob Chemother; 2004 Aug; 54(2):406-9. PubMed ID: 15201232
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the E166A mutant of extended-spectrum beta-lactamase Toho-1 at 1.8 A resolution.
Ibuka A; Taguchi A; Ishiguro M; Fushinobu S; Ishii Y; Kamitori S; Okuyama K; Yamaguchi K; Konno M; Matsuzawa H
J Mol Biol; 1999 Feb; 285(5):2079-87. PubMed ID: 9925786
[TBL] [Abstract][Full Text] [Related]
10. Structure-function studies of arginine at position 276 in CTX-M beta-lactamases.
Pérez-Llarena FJ; Cartelle M; Mallo S; Beceiro A; Pérez A; Villanueva R; Romero A; Bonnet R; Bou G
J Antimicrob Chemother; 2008 Apr; 61(4):792-7. PubMed ID: 18281307
[TBL] [Abstract][Full Text] [Related]
11. Structural insights into substrate recognition and product expulsion in CTX-M enzymes.
Delmas J; Leyssene D; Dubois D; Birck C; Vazeille E; Robin F; Bonnet R
J Mol Biol; 2010 Jul; 400(1):108-20. PubMed ID: 20452359
[TBL] [Abstract][Full Text] [Related]
12. High diversity of extended-spectrum beta-lactamases among clinical isolates of Enterobacteriaceae from Portugal.
Machado E; Coque TM; Cantón R; Novais A; Sousa JC; Baquero F; Peixe L;
J Antimicrob Chemother; 2007 Dec; 60(6):1370-4. PubMed ID: 17913717
[TBL] [Abstract][Full Text] [Related]
13. Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases.
Aragón LM; Mirelis B; Miró E; Mata C; Gómez L; Rivera A; Coll P; Navarro F
J Antimicrob Chemother; 2008 May; 61(5):1029-32. PubMed ID: 18292096
[TBL] [Abstract][Full Text] [Related]
14. Prediction of the evolution of ceftazidime resistance in extended-spectrum beta-lactamase CTX-M-9.
Delmas J; Robin F; Carvalho F; Mongaret C; Bonnet R
Antimicrob Agents Chemother; 2006 Feb; 50(2):731-8. PubMed ID: 16436733
[TBL] [Abstract][Full Text] [Related]
15. Natural D240G Toho-1 mutant conferring resistance to ceftazidime: biochemical characterization of CTX-M-43.
Celenza G; Luzi C; Aschi M; Segatore B; Setacci D; Pellegrini C; Forcella C; Amicosante G; Perilli M
J Antimicrob Chemother; 2008 Nov; 62(5):991-7. PubMed ID: 18755695
[TBL] [Abstract][Full Text] [Related]
16. Predictive analysis of ceftazidime hydrolysis in CTX-M-type beta-lactamase family members with a mutational substitution at position 167.
Kimura S; Ishii Y; Tateda K; Yamaguchi K
Int J Antimicrob Agents; 2007 Mar; 29(3):326-31. PubMed ID: 17258896
[TBL] [Abstract][Full Text] [Related]
17. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
[TBL] [Abstract][Full Text] [Related]
18. Extended-spectrum beta-lactamases in North America, 1987-2006.
Bush K
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():134-43. PubMed ID: 18154537
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of extended-spectrum beta-lactamase Toho-1: insights into the molecular mechanism for catalytic reaction and substrate specificity expansion.
Ibuka AS; Ishii Y; Galleni M; Ishiguro M; Yamaguchi K; Frère JM; Matsuzawa H; Sakai H
Biochemistry; 2003 Sep; 42(36):10634-43. PubMed ID: 12962487
[TBL] [Abstract][Full Text] [Related]
20. Resistance of strains producing extended-spectrum beta-lactamases and genotype distribution in China.
Yu Y; Ji S; Chen Y; Zhou W; Wei Z; Li L; Ma Y
J Infect; 2007 Jan; 54(1):53-7. PubMed ID: 16533535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
